A company based in the Research Triangle Park developing sensors for critical medical procedures has raised $200,000 in a private debt offering, according to a filing with the Securities and Exchange Commission.

Clinical Sensors Inc. raised the money from one investor. It is seeking to raise another $200,000, according to the filing.

The company is developing sensors that hold the potential to identify and monitor patients at risk of developing life-threatening conditions at an early stage. Its first products are aimed at hospital-acquired infections and diabetes.

In April, the company was awarded two small business research grants from the National Institutes of Health that provide over $1.5 million to support its continued development and demonstration of its point-of-care device that measures a patient’s blood nitric oxide level within a few seconds.

Dr. Philippe Chemla is the chief executive officer of the company.

Prior to joining Clinical Sensors, Chemla served as vice president of business development at Metabolon where he established strategic partnerships with industry segment leaders. Cemla also held leadership positions at Fujifilm Diosynth Biotechnology, Ciba, Novartis and Syngenta.

The company was founded by UNC-Chapel Hill chemistry professor Mark Schoenfisch, who serves as its president. He is an expert in electrochemical sensors, nitric oxide, and bio-functional membranes.

Private companies such as Clinical Sensors relying on a Reg D exemption do not have to register their offering of securities with the SEC, but must file a Form D electronically with the SEC after they sell its securities.